Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis gets 4% sales lift as 'growth products' make good on their label

Novartis' third-quarter profit may have gotten a large boost from the sale of its Idenix stake to Merck this summer, with cost cuts kicking in, too. But when it comes to top-line results that topped analysts' forecasts, the company has its own hot sellers to thank.

Australia's CSL gets three Novartis vaccine plants in $275M deal

For $275 million, Australia's CSL is buying from Novartis a network of vaccine manufacturing facilities, as well as a portfolio of products.

Novartis chief Jimenez predicts 'multi-blockbuster' success for star heart drug

Novartis' pharma chief has hailed the company's forthcoming heart failure treatment as "the most exciting launch the company has ever had," and now the drugmaker's CEO has declared a "multi-blockbuster" in the making, joining a chorus of analysts who expect billions in annual sales from LCZ696.

Pharma's top 10 M&A deals of 2014's first half

Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of...

Novartis officially bows out of vaccines with flu sale to CSL

Novartis' 8-year foray into vaccines is officially coming to a close. After divesting the bulk of its unit to GlaxoSmithKline in an April deal, the pharma giant Sunday announced it had agreed to sell its flu shot business to Australia's CSL. And with that, it'll make its exit from a field that's given it trouble since its Chiron buyout in 2006.

Novartis unloads last piece of vaccines puzzle to CSL for $275M

After a lengthy strategic review and a handful of divestments, Novartis' slim-down effort is finally coming to a close. The company has sold off its flu vaccines business--the only piece of the vaccines unit it hung onto after a multibillion-dollar April transaction with GlaxoSmithKline--to Australia's CSL.

Novartis racks up a new slate of promising PhIII data for secukinumab

Just days after an FDA advisory group gave its unanimous blessing to Novartis for secukinumab (AIN457) as a new treatment for plaque psoriasis, the pharma giant has produced a new slate of Phase III data backing the IL-17 therapy for ankylosing spondylitis.

Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

Novartis hopes to rev up Theraflu relaunch with TV celeb Nick Cannon

Novartis has the face to launch a Theraflu comeback: entertainer Nick Cannon, who's advising Americans to get ready for flu season by getting vaccinated and stocking up on the over-the-counter remedy.

Novartis recruits Nick Cannon for double-whammy flu campaign

In choosing a face for its new Theraflu Fluprint campaign, Novartis Consumer Health was on the hunt for someone who understood the importance of being flu-ready--and who used Theraflu products, of course, company spokeswoman Liz Power told FiercePharmaMarketing.